Tranzyme shares dive as bowel drug ulimorelin misses PhIII endpoint
This article was originally published in Scrip
Executive Summary
Shares of Tranzyme Pharma plunged after the firm’s lead drug candidate, the intravenous ghrelin agonist, ulimorelin, failed to meet its primary efficacy endpoint of accelerating recovery of GI function versus placebo in the Phase III ULISES 007 trial of subjects who have undergone bowel resection surgery.